Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Glycopeptide antibiotics Stories

2014-04-03 12:27:08

Lipoglycopeptides Dalvance and Oritavancin Will Find Favorable Uptake as Convenient Outpatient Anti-MRSA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that following its launch, Cubist's second generation oxazolidinone Sivextro will be highly differentiated from other anti-MRSA (methicillin-resistant Staphylococcus aureus) agents for the treatment of complicated skin and skin structure infections...

2013-12-14 23:01:35

MarketResearchReports.Biz announces addition of new report “Skin And Skin Structure Infections (SSSI) Caused By Bacteria 2013” to its database. Visit http://www.marketresearchreports.biz/analysis-details/skin-and-skin-structure-infections-sssi-caused-by-bacteria-pipeline-review-h2-2013. Albany, NY (PRWEB) December 14, 2013 Global Markets Directs, 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria Pipeline Review, H2 2013', provides an overview of the indications...

2013-12-10 08:30:14

AUSTIN, Texas, Dec. 10, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. The company also received Fast Track designation for AeroVanc pursuant to section 506(a)(1) of the Food and Drug...

2013-12-05 08:29:37

AUSTIN, Texas, Dec. 5, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today that the company has appointed Dr. Joseph S. McCracken, DVM and Yuri Pikover to its Board of Directors. Dr. McCracken has more than 25 years of experience in technical, business development and market development roles with biotechnology and pharmaceutical companies. Most recently he was Global Head of Business Development & Licensing at Roche Pharmaceuticals where he was responsible for Roche's...

2013-11-19 08:26:14

New Long-Acting Agents Are Poised to Challenge the Position of IV Vancomycin and Cubist's Cubicin in the OPAT Market, According to a New Report from Decision Resources Group BURLINGTON, Mass., Nov. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than three-quarters of surveyed physicians anticipate prescribing Durata's dalbavancin and The Medicines Company's oritavancin as...

2013-10-17 08:29:27

AUSTIN, Texas, Oct. 17, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today it has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation. The award will advance the development of AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of people with cystic fibrosis (CF) who have persistent methicillin-resistant Staphylococcus...

2013-09-10 08:29:55

- Novel Locilex(TM) Formulation Demonstrates Favorable Stability at 18 Month Testing NEW YORK, Sept. 10, 2013 /PRNewswire/ -- Dipexium Pharmaceuticals, LLC today announced modifications made to the Locilex(TM) (pexiganan acetate cream 1%) formulation have resulted in favorable chemical and physical stability as noted in 18-month stability testing by its manufacturer. Stability Trend Analyses at 18 months suggest a Locilex(TM) shelf-life of at least 36 months at room temperature....

2013-09-04 20:21:55

AUSTIN, TX and TORONTO, ON, Sept. 4, 2013 /PRNewswire/ - Affinium Pharmaceuticals ("Affinium") announced today that it has initiated dosing in a Phase 1 intravenous (IV) clinical trial of its new antibiotic prodrug, AFN-1720.  AFN-1720 is the prodrug of the active drug, AFN-1252.  Initiation of this IV clinical study follows Affinium's 2012 successful oral Phase 2a clinical study demonstrating excellent safety, efficacy and tolerability in acute bacterial skin and skin structure...

2013-08-22 04:21:55

-- Funds U.S. Development of MRX-I Next-Generation Antibiotic -- HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures. Proceeds...

Absorbent Nanofibers Show Promise In Brain Infection Treatment
2013-08-08 05:39:01

April Flowers for redOrbit.com - Your Universe Online A team of scientists, led by Chang Gung University, report a plastic material already used in absorbent surgical sutures and other medical devices shows promise for continuous administration of antibiotics to patients with brain infections. The findings, reported in ACS Chemical Neuroscience, show the use of the material, placed directly on the brain's surface, could reduce the need for weeks of costly hospital stays now required for...